BDKRB1 and neoplasm: KLK1 administration significantly reversed the accumulation of ECM and enhanced its anti‐fibrotic and matrix remodeling effects in the context of tumor growth promotion, while administration of the B1R inhibitor SSR240612 on this basis found that ECM‐related indicators were not significantly restored, indicating that the conduction of the KLK1‐B1R axis signaling axis was hindered.